Back to Authors

Hadley, Gail

Mayo Clinic

Vascular Ultrasound Core-Laboratory (VasCore), Boston, MA, USA

Citations 1

Relationships between the use of pharmacomechanical catheter-directed thrombolysis, sonographic findings, and clinical outcomes in patients with acute proximal DVT: Results from the ATTRACT Multicenter Randomized Trial
Weinberg, Ido , Salter, Amber , Hadley, Gail, Al‐Hammadi, Noor , Kearon, Clive, Julian, Jim A. , Gornik, Heather L. , Goldhaber, Samuel Z. , Comerota, Anthony J. , Kindzelski, Andrei, Schainfeld, Robert M. , Angle, John F. , Misra, Sanjay , Schor, Jonathan , Hurst, Darren, Investigators, for the ATTRACT Trial, Gornik, Heather L , Misra, Sanjay , Vedantham, Suresh , Razavi, Mahmood K. , Jaff, Michael R. , Investigators, for the ATTRACT Trial

Vascular Medicine | July 27, 2019 | Volume: 24 | Issue: 5 | Pages: 442-451

10.1177/1358863x19862043 Get It

Few studies have documented relationships between endovascular therapy, duplex ultrasonography (DUS), post-thrombotic syndrome (PTS), and quality of life (QOL). The Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT) trial randomized 692 patients with acute proximal deep vein thrombosis (DVT) to receive anticoagulation or anticoagulation plus pharmacomechanical catheter-directed thrombolysis (PCDT). Compression DUS was obtained at baseline, 1 month and 12 months. Reflux DUS was obtained at 12 months in a subset of 126 patients. Clinical outcomes were collected over 24 months. At 1 month, patients who received PCDT had less residual thrombus compared to Control patients, evidenced by non-compressible common femoral vein (CFV) (21% vs 35%, p < 0.0001), femoral vein (51% vs 70%, p < 0.0001), and popliteal vein (61% vs 74%, p < 0.0001). At 12 months, in the ultrasound substudy, valvular reflux prevalence was similar between groups (85% vs 91%, p = 0.35). CFV non-compressibility at 1 month was associated with higher rates of any PTS (61% vs 46%, p < 0.001), a higher incidence of moderate-or-severe PTS (30% vs 19%, p = 0.003), and worse QOL (difference 8.2 VEINES-QOL (VEnous INsufficiency Epidemiological and Economic Study on Quality of Life) points; p = 0.004) at 24 months. Valvular reflux at 12 months was associated with moderate-or-severe PTS at 24 months (30% vs 0%, p = 0.01). In summary, PCDT results in less residual thrombus but does not reduce venous valvular reflux. CFV non-compressibility at 1 month is associated with more PTS, more severe PTS, and worse QOL at 24 months. Valvular reflux may predispose to moderate-or-severe PTS. ClinicalTrials.gov Identifier NCT00790335.